Daily Stock Analysis, ALNY, Alnylam Pharmaceuticals Inc, priceseries

Alnylam Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
53.38
Close
52.47
High
53.58
Low
51.68
Previous Close
53.17
Daily Price Gain
-0.70
YTD High
60.41
YTD High Date
Mar 21, 2017
YTD Low
35.98
YTD Low Date
Jan 31, 2017
YTD Price Change
13.83
YTD Gain
35.79%
52 Week High
80.11
52 Week High Date
Sep 20, 2016
52 Week Low
31.38
52 Week Low Date
Nov 3, 2016
52 Week Price Change
-6.31
52 Week Gain
-10.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 17. 2015
96.68
Feb 27. 2015
101.61
8 Trading Days
5.10%
Link
LONG
Apr 8. 2015
106.50
Apr 27. 2015
114.04
13 Trading Days
7.08%
Link
LONG
Jul 10. 2015
121.77
Jul 24. 2015
130.70
10 Trading Days
7.33%
Link
LONG
Aug 27. 2015
104.90
Aug 31. 2015
110.93
2 Trading Days
5.75%
Link
LONG
Mar 31. 2016
62.77
Apr 11. 2016
67.17
7 Trading Days
7.01%
Link
LONG
May 23. 2016
56.07
Jun 9. 2016
67.28
12 Trading Days
19.99%
Link
LONG
Nov 7. 2016
36.26
Nov 23. 2016
43.84
12 Trading Days
20.89%
Link
LONG
Feb 24. 2017
46.62
Mar 13. 2017
50.52
11 Trading Days
8.37%
Link
Company Information
Stock Symbol
ALNY
Exchange
NasdaqGS
Company URL
http://www.alnylam.com
Company Phone
(617) 551-8200
CEO
John M. Maraganore
Headquarters
Massachusetts
Business Address
300 THIRD STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001178670
About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company's clinical development programs include Patisiran and Revusiran, which are in Phase ...

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company's clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the treatment of hepatic porphyrias. Its product development programs also include ALN-AAT for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia; ALN-HBV for the treatment of Hepatitis B virus; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Ionis Pharmaceuticals, Inc.; Novartis Pharma AG; Novartis/Arrowhead; F. Hoffmann-La Roche Ltd; Roche/Arrowhead; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Ascletis BioScience Co., Ltd.; Monsanto Company; Sanofi Genzyme; The Medicines Company; Arbutus Biopharma Corporation; Protiva Biotherapeutics, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.